From the Journals

New Guideline Offers Recommendations for Alcohol-Associated Liver Disease


 

Policy Implications

Dr. Jophlin and colleagues noted the importance of policy aimed at alcohol use reduction, multidisciplinary care for AUD and ALD, and additional research around severe AH.

“As a practicing transplant hepatologist and medical director of a liver transplant program in the heart of Bourbon country, I am a part of just one healthcare team experiencing ALD, particularly AH, as a mass casualty event. Healthcare teams are fighting an unrelenting fire that the alcohol industry is pouring gasoline on,” Dr. Jophlin said. “It is imperative that healthcare providers have a voice in the policies that shape this preventable disease. We hope these guidelines inspire practitioners to explore our influence on how alcohol is regulated, marketed, and distributed.”

Additional interventions and public policy considerations could help reduce alcohol-related morbidity and mortality at a moment when the characteristics of those who present with AUD appear to be evolving.

“The typical person I’m seeing now is not someone who has been drinking heavily for decades. Rather, it’s a young person who has been drinking heavily for many months or a couple of years,” said James Burton, MD, a professor of medicine at the University of Colorado School of Medicine and medical director of liver transplantation at the University of Colorado Hospital’s Anschutz Medical Campus in Aurora.

Dr. Burton, who wasn’t involved with the guideline, noted it’s become more common for people to drink multiple alcoholic drinks per day for multiple times per week. Patients often don’t think it’s a problem, even as he discusses their liver-related issues.

“We can’t just keep living and working the way we were 10 years ago,” he said. “We’ve got to change how we approach treatment. We have to treat liver disease and AUD.”

The guideline was supported by several National Institutes of Health grants and an American College of Gastroenterology faculty development grant. The authors declared potential competing interests with various pharmaceutical companies. Dr. Burton reported no financial disclosures.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

Be aware of hepatic encephalopathy, dementia overlap in older patients with cirrhosis
MDedge Family Medicine
Exercise training reduces liver fat in patients with NAFLD, even without weight loss
MDedge Family Medicine
CDC recommends screening all adults for hepatitis B
MDedge Family Medicine
Likely cause of mysterious hepatitis outbreak in children identified
MDedge Family Medicine
Racial disparities not found in chronic hepatitis B treatment initiation
MDedge Family Medicine
Dried blood spot test validated for HIV, hep B, and hep C
MDedge Family Medicine
‘Exciting time for NASH’ with resmetirom phase 3 results
MDedge Family Medicine
Food insecurity increases risk of adolescent MASLD
MDedge Family Medicine
Is There a Safe Alcohol Limit in Early Liver Disease?
MDedge Family Medicine
The Breakthrough Drug Whose Full Promise Remains Unrealized
MDedge Family Medicine